Sprint Bioscience AB (publ) (SPRINT.ST)
ValueMarkers Composite Index
DCF data not available
Sprint Bioscience AB (publ) (SPRINT.ST) — VMCI valuation read
Headline read on SPRINT.ST: VMCI of 58/100 versus a Healthcare sector median of 50. The 8-point above-median position is what makes Sprint Bioscience AB (publ) a relative-value candidate in the mid-cap cohort, before any pillar-level review.
Form 4 filings on SPRINT.ST: zero in the trailing 30 days. The absence of insider transactions is itself a data point, just a low-information one. The thesis runs on financials and price action until that changes.
**Investor frame.** Three reads on SPRINT.ST: value (SPRINT.ST trades at 27.0x earnings, 50% above the Healthcare median of 18.0x), quality (ROIC of 19.0% sits 9.0pp above the Healthcare median (10.0%)), and risk (net debt to EBITDA of 3.5x is the binding constraint on the bear case). The value read also implies an EV/EBITDA gap of +4.0x against the Healthcare 12.0x baseline.
SPRINT.ST rose 1.8% over the trailing 7 days, with a -9.6% read on a 30-day basis.
Related Stocks in Healthcare
Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.